Lila Levinson, PhD,  Science Writer—

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.

Articles by Lila Levinson, PhD

Partnership to advance Infudopa SubC drug-device combination

Neuraxpharm is partnering with Dizlin Pharmaceuticals on Dizlin’s Infudopa SubC drug-device combination therapy, which allows for continuous levodopa-carbidopa delivery in people with advanced Parkinson’s disease. Infudopa SubC is a wearable device being developed for patients who experience fluctuations in their Parkinson’s motor symptoms despite treatment. “Our…

Theater-based therapy improves emotional well-being in Parkinson’s

An experimental theater program improved the emotional well-being of people with Parkinson’s disease, and eased their anxiety and depression, a study reports. “Arts-based interventions could offer a novel, efficient, and inexpensive tool to complement pharmacological therapy,” the study’s researchers wrote. The program outperformed an at-home memory and attention program at…

Cough medicine may help some with Parkinson’s dementia: Trial

Ambroxol, a common cough medicine, may help stabilize neuropsychiatric symptoms in Parkinson’s disease dementia (PDD) and shows cognitive promise for patients with mutations in the GBA1 gene, according to results from a Phase 2 clinical trial. While ambroxol is widely used in Europe to treat respiratory conditions, it’s not approved…

Bezisterim clinical trial uses hybrid design to promote accessibility

BioVie’s ongoing SUNRISE-PD clinical trial of bezisterim in early Parkinson’s disease uses a hybrid, decentralized approach to center patient experience and promote accessibility, according to the company. Parkinson’s disease patients often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and…

Ambio ibogaine program treats Parkinson’s, other diseases

A new clinical program will use ibogaine, a naturally occurring psychedelic, to treat neurodegenerative conditions including Parkinson’s disease. Ambio Life Sciences, which hosts other ibogaine programming and participates in scientific research about the drug, soft-launched the program in February. It is the first of its kind in the…